AstraZeneca Invests Over $1.6 Million With Business Objects for E-Business Intelligence Solution; Business Objects Helps Speed the Development of Essential Pharmaceuticals.Business Editors/High-Tech Writers SAN JOSE San Jose, city, United States San Jose (sănəzā`, săn hōzā`), city (1990 pop. 782,248), seat of Santa Clara co., W central Calif.; founded 1777, inc. 1850. , Calif.--(BUSINESS WIRE)--May 15, 2001 AstraZeneca, one of the world's largest pharmaceutical companies, has signed a contract worth more than $1.6 million with Business Objects (Nasdaq:BOBJ BOBJ Business Objects SA ), the world's leading provider of e-business intelligence (e-BI) solutions, to increase the efficiency of information sharing See data conferencing. to aid in the development of pharmaceutical products. AstraZeneca is using BusinessObjects(TM), the integrated query, reporting, and analysis solution for the enterprise from Business Objects, to transform the way in which its pharmaceutical development teams capture, share and exploit critical scientific data. The transaction occurred in December 2000. AstraZeneca has an annual turnover of almost $16 billion and develops, manufactures, and markets many of the world's most prominent pharmaceutical medicines. AstraZeneca is using BusinessObjects to capitalize on Cap´i`tal`ize on` v. t. 1. To turn (an opportunity) to one's advantage; to take advantage of (a situation); to profit from; as, to capitalize on an opponent's mistakes s>. its consolidated worldwide research and development function by enabling scientists, project teams, and managers to undertake powerful analysis, query, and reporting of R&D data, to share this information with other development teams within the organization. As a result, AstraZeneca is increasing the efficiency of its R&D activity, helping to speed the delivery of breakthrough pharmaceutical remedies to patients across the globe. AstraZeneca plans to use BusinessObjects to support many of its primary R&D functions, including reporting on clinical trials, drug safety, and project budgeting. Business Objects is also providing AstraZeneca with training, implementation, and development support. "We invest over $8 million every day in R&D and it is vital that we realize the true value of our data," said Andy Woods, head of IS for Development at AstraZeneca's Charnwood division. "Using Business Objects enables our research and development teams to access the information they need to undertake specific data analysis and to share this information across the entire organization in the form of easy to use reports." "By delivering this capability widely across our pharmaceutical development teams we are empowering our people by turning them from information consumers to information power users," said Woods. "This change will contribute to delivering increased efficiency in our business and in our ability to realize the true potential of our R&D efforts." "AstraZeneca joins the growing number of leading edge organizations that are benefiting from the availability of key information through the adoption of Business Objects as their e-business intelligence platform," said Tony Heyworth, UK marketing director at Business Objects. "AstraZeneca is now able to put relevant, accurate, and timely information into the hands of the right people where and when they need it." About AstraZeneca AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $15.8 billion and leading positions in sales of gastrointestinal gastrointestinal /gas·tro·in·tes·ti·nal/ (-in-tes´ti-n'l) pertaining to or communicating with the stomach and intestine. gas·tro·in·tes·ti·nal adj. Abbr. , oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. , anesthesia anesthesia (ănĭsthē`zhə) [Gr.,=insensibility], loss of sensation, especially that of pain, induced by drugs, especially as a means of facilitating safe surgical procedures. (including pain management), cardiovascular, central nervous system (CNS See Continuous net settlement. CNS See continuous net settlement (CNS). ) and respiratory products. About Business Objects Business Objects is the world's leading provider of e-business intelligence (e-BI) solutions. The company coined the term e-business Intelligence in 1998 to describe the intersection intersection /in·ter·sec·tion/ (-sek´shun) a site at which one structure crosses another. intersection a site at which one structure crosses another. of business intelligence and the internet. Using e-business intelligence, organizations can access, analyze, and share information in intranet, extranet, and e-business environments. In intranets, the company's products provide employees with information to make better business decisions, and are used in environments ranging from workgroups of 20 users to enterprise deployments exceeding 20,000. In the extranet environment, the company is pioneering the use of e-BI in applications that allow organizations to build stronger relationships by linking customers, partners, and suppliers via the internet. In addition, the company's products can improve the performance of an e-business by providing reporting and analysis against the ever-expanding amount of transaction and profile data that is collected each day throughout the world wide web. Founded in 1990, Business Objects pioneered the modern business intelligence industry by inventing and patenting a "semantic layer Semantic Layer The semantic layer is a business representation of corporate data that helps end users access data autonomously using common business terms. Developed and patented by Business Objects, it maps complex data into familiar business terms such as product, " that insulates users from the technical complexity of database systems. Today, the company has over 13,100 customers in more than 80 countries. The company's stock is publicly traded under the ticker symbols Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors NASDAQ: BOBJ and Euronext Paris Euronext Paris is France's securities market, formerly known as the Paris Bourse, which merged with the Amsterdam and Brussels exchanges in September 2000 to form Euronext NV, which is the second largest exchange in Europe behind the London Stock Exchange. : code Euroclear France 12074 and included in the SBF SBF Studium Biblicum Franciscanum (Franciscan School of Biblical Investigations; Jerusalem, Israel) SBF Small Block Ford (automotive engine) SBF Single Black Female SBF Société des Bourses Francaises 120 and IT CAC See Consumer Advisory Council. 50 French stock market indexes. Business Objects can be reached at 408/953-6000 and http://www.businessobjects.com. Note to Editors: WebIntelligence and BusinessObjects are registered trademarks of Business Objects SA. Other company and product names may be trademarks of the respective companies with which they are associated. A full-text copy of this announcement may be obtained by calling the Business Objects fax retrieval line at 800/414-2114 and selecting option "two." The announcement may also be downloaded from the web; access http://www.businesswire.com/cnn and search on "Business Objects." Business Objects product inquiries should contact 800/527-0580. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion